Yüklüyor......
Clinical Outcomes in Recurrent Glioblastoma with Bevacizumab therapy: An Analysis of the Literature
Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous review (995 patients) estimated a progression free...
Kaydedildi:
| Yayımlandı: | J Clin Neurosci |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581989/ https://ncbi.nlm.nih.gov/pubmed/28711289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jocn.2017.06.070 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|